Loading evidence section…
Supporting records preserved for this report
22 locally preserved candidate records. Metadata adds research context; it is not a medical claim.
Bone destruction from primary or metastatic cancer is associated with severe pain that is difficult to treat. Opioids are often used for cancer pain but are associated with many serious side effects, and non-opioid alternatives are needed. We will determine the effectiveness and mechanisms underlying antinociceptive properties of Resolvin D1 in a mouse model of bone cancer pain.
PROJECT NARRATIVE Controversy exists over the risk to benefit ratio of medical marijuana for adults with chronic non-cancer pain (CNCP) on chronic opioid therapy (COT). The primary goal of this proposal is to assess whether medical marijuana, when added to a behavioral prescription opioid taper support program, improves pain and reduces opioid dose in adults on COT for CNCP more so than the behavioral intervention alone. This information is critical to better inform patients and clinicians about the extent to which medical marijuana use may be beneficial or harmful to this patient population.
Relevance to public health: Pain occurs as the spread of cancer cells destroys tissue, and bone pain is among the most severe. Novel strategies are needed to treat cancer pain because of limitations to the use of opioids. Cannabinoids are potent analgesics, and manipulation of the metabolism of endogenous cannabinoids may provide an effective strategy for reducing mechanical hypersensitivity in patients where destruction of bone is involved.
Pain occurs as the spread of cancer cells destroys tissue, and bone pain is among the most severe. Novel strategies are needed to treat cancer pain because of limitations to the use of opioids. Cannabinoids are potent analgesics, and manipulation of the metabolism of endogenous cannabinoids may provide an effective strategy for reducing mechanical hypersensitivity in patients where destruction of bone is involved.
NARRATIVE The proposed study fills a major gap in knowledge about how state medical and adult-use (i.e., recreational) cannabis laws have impacted opioid receipt and pain outcomes in cancer. We will triangulate findings from a quantitative policy evaluation with information from surveys and interviews that explore cancer centers’ implementation of state cannabis laws, physicians’ practices for recommending, and patients’ practices for using cannabis for cancer pain. To inform a rapidly evolving policy landscape—in which states are continuously considering, enacting, or expanding cannabis laws— it is essential to understand how these laws affect pain management practices and outcomes for patients with cancer as one of the largest groups of consumers of therapeutic cannabis.
Relevance to public health: Pain occurs as the spread of cancer cells destroys tissue, and bone pain is among the most severe. Novel strategies are needed to treat cancer pain because of limitations to the use of opioids. Cannabinoids are potent analgesics, and manipulation of the metabolism of endogenous cannabinoids may provide an effective strategy for reducing mechanical hypersensitivity in patients where destruction of bone is involved.
Project Narrative This controlled clinical trial will investigate whether cannibidiol (CBD) is safe and effective in helping patients with chronic non-cancer pain (CNCP) disorders (who are maintained on moderate to high-doses of opioid pain medication) reduce or eliminate their chronic opioid therapy (COT) and whether CBD will be effective in reducing pain in this patient population. This investigation is significant from a public health perspective because given the limited efficacy to high risk profile of COT in CNCP, there is an urgent need to develop novel, safe, and non-addictive, non-opioid pharmacotherapies that can both reduce the dose of maintenance prescription opioids and pain in patients with CNCP syndromes.
NARRATIVE The proposed study fills a major gap in knowledge about how state medical and adult-use (i.e., recreational) cannabis laws have impacted opioid receipt and pain outcomes in cancer. We will triangulate findings from a quantitative policy evaluation with information from surveys and interviews that explore cancer centers’ implementation of state cannabis laws, physicians’ practices for recommending, and patients’ practices for using cannabis for cancer pain. To inform a rapidly evolving policy landscape—in which states are continuously considering, enacting, or expanding cannabis laws— it is essential to understand how these laws affect pain management practices and outcomes for patients with cancer as one of the largest groups of consumers of therapeutic cannabis.
PROJECT NARRATIVE Controversy exists over the risk to benefit ratio of medical marijuana for adults with chronic non-cancer pain (CNCP) on chronic opioid therapy (COT). The primary goal of this proposal is to assess whether medical marijuana, when added to a behavioral prescription opioid taper support program, improves pain and reduces opioid dose in adults on COT for CNCP more so than the behavioral intervention alone. This information is critical to better inform patients and clinicians about the extent to which medical marijuana use may be beneficial or harmful to this patient population.
Oral cancer pain, whose prevalence and intensity of pain is greater than that of other cancers, is a debilitating condition and a significant clinical challenge, in part because even the most efficacious of the currently available remedies are limited by their side effects profile. We have developed a novel class of drugs free of central nervous system side effects for treating cancer pain and propose to optimize these drugs leading to an investigational new drug (IND) approval.
PROJECT NARRATIVE Controversy exists over the risk to benefit ratio of medical marijuana for adults with chronic non-cancer pain (CNCP) on chronic opioid therapy (COT). The primary goal of this proposal is to assess whether medical marijuana, when added to a behavioral prescription opioid taper support program, improves pain and reduces opioid dose in adults on COT for CNCP more so than the behavioral intervention alone. This information is critical to better inform patients and clinicians about the extent to which medical marijuana use may be beneficial or harmful to this patient population.
PROJECT NARRATIVE Controversy exists over the risk to benefit ratio of medical marijuana for adults with chronic non-cancer pain (CNCP) on chronic opioid therapy (COT). The primary goal of this proposal is to assess whether medical marijuana, when added to a behavioral prescription opioid taper support program, improves pain and reduces opioid dose in adults on COT for CNCP more so than the behavioral intervention alone. This information is critical to better inform patients and clinicians about the extent to which medical marijuana use may be beneficial or harmful to this patient population.
Bone destruction from primary or metastatic cancer is associated with severe pain that is difficult to treat. Opioids are often used for cancer pain but are associated with many serious side effects, and non-opioid alternatives are needed. We will determine the effectiveness and mechanisms underlying antinociceptive properties of Resolvin D1 in a mouse model of bone cancer pain.
Bone destruction from primary or metastatic cancer is associated with severe pain that is difficult to treat. Opioids are often used for cancer pain but are associated with many serious side effects, and non-opioid alternatives are needed. We will determine the effectiveness and mechanisms underlying antinociceptive properties of Resolvin D1 in a mouse model of bone cancer pain.
PROJECT NARRATIVE Controversy exists over the risk to benefit ratio of medical marijuana for adults with chronic non-cancer pain (CNCP) on chronic opioid therapy (COT). The primary goal of this proposal is to assess whether medical marijuana, when added to a behavioral prescription opioid taper support program, improves pain and reduces opioid dose in adults on COT for CNCP more so than the behavioral intervention alone. This information is critical to better inform patients and clinicians about the extent to which medical marijuana use may be beneficial or harmful to this patient population.
Project Narrative This controlled clinical trial will investigate whether cannibidiol (CBD) is safe and effective in helping patients with chronic non-cancer pain (CNCP) disorders (who are maintained on moderate to high-doses of opioid pain medication) reduce or eliminate their chronic opioid therapy (COT) and whether CBD will be effective in reducing pain in this patient population. This investigation is significant from a public health perspective because given the limited efficacy to high risk profile of COT in CNCP, there is an urgent need to develop novel, safe, and non-addictive, non-opioid pharmacotherapies that can both reduce the dose of maintenance prescription opioids and pain in patients with CNCP syndromes.
Relevance to public health: Pain occurs as the spread of cancer cells destroys tissue, and bone pain is among the most severe. Novel strategies are needed to treat cancer pain because of limitations to the use of opioids. Cannabinoids are potent analgesics, and manipulation of the metabolism of endogenous cannabinoids may provide an effective strategy for reducing mechanical hypersensitivity in patients where destruction of bone is involved.
Bone destruction from primary or metastatic cancer is associated with severe pain that is difficult to treat. Opioids are often used for cancer pain but are associated with many serious side effects, and non-opioid alternatives are needed. We will determine the effectiveness and mechanisms underlying antinociceptive properties of Resolvin D1 in a mouse model of bone cancer pain.
Bone destruction from primary or metastatic cancer is associated with severe pain that is difficult to treat. Opioids are often used for cancer pain but are associated with many serious side effects, and non-opioid alternatives are needed. We will determine the effectiveness and mechanisms underlying antinociceptive properties of Resolvin D1 in a mouse model of bone cancer pain.